Company: NUTR
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001641172-25-012203
Chunk: 220

Company: NUSATRIP Inc
Filing Date: 2025-05-23
Form: S-1/A
Chunk 220
---
                                                                                                                                 
 will not receive any proceeds from the sales of outstanding Common Stock by the Selling Stockholders.                              |
| Risk                                            
 factors:                                        |     | Investing                                                                                                                          
 in our Common Stock involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment. 
 You should carefully consider the information set forth in the “Risk Factors” section beginning on page 15 before                  
 deciding to invest in our Common Stock.                                                                                            |
| Trading                                         
 market and symbol:                              |     | We                                                                                                                                 
 intend to list our Common Stock on the Nasdaq “NUTR” Market under the symbol “NUTR”. We believe that upon                          
 the completion of the Company’s initial public offering, we will meet the standards for listing on Nasdaq. The closing of the      
 initial public offering is contingent upon the successful listing of our Common Stock on Nasdaq.                                   |

(1) The number of shares of our Common Stock outstanding prior to this offering, as set forth in the table above, is based on the shares outstanding as of the date of this prospectus.

| Alt-1 |

<div align='center'>[Alternate Page for Resale Prospectus]

USE OF PROCEEDS</div>

We will not receive any proceeds from the sale of Common Stock by the Selling Stockholders. In addition, the underwriters will not receive any compensation from the sale of the Common Stock by the Selling Stockholders. The Selling Stockholders will receive all of the net proceeds from the sales of Common Stock offered by it under this prospectus.

The Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred by them in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees and fees and expenses of our counsel and our accountants.

| Alt-2 |

<div align='center'>[Alternate Page for Resale Prospectus]

SELLING STOCKHOLDERS</div>

The shares of Common Stock being offered by the Selling Stockholders are those held by the Selling Stockholders or issuable to the Selling Stockholders upon the exercise of certain convertible notes, that are convertible into shares of Common Stock, held by the Selling Stockholders or automatic conversion of certain convertible notes into shares of Common Stock held by the Selling Stockholders. On October 18, 2024,